Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 16,075 Shares

Key Points

• Jack Bendheim, CEO of Phibro Animal Health, sold a total of 16,075 shares on October 20th for approximately $649,108, reducing his ownership by 40.21%.
• Phibro Animal Health recently reported a quarterly EPS of $0.57, exceeding estimates, and had revenue of $378.70 million for the quarter, surpassing analyst expectations.
• The company announced a quarterly dividend of $0.12, representing a yield of 1.2% and a payout ratio of 40.68%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 16,075 shares of the firm's stock in a transaction on Monday, October 20th. The stock was sold at an average price of $40.38, for a total value of $649,108.50. Following the transaction, the chief executive officer owned 23,899 shares in the company, valued at $965,041.62. The trade was a 40.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jack Bendheim also recently made the following trade(s):

• On Friday, October 17th, Jack Bendheim sold 700 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.03, for a total value of $28,021.00.
• On Thursday, September 18th, Jack Bendheim sold 7,022 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.26, for a total value of $282,705.72.
• On Wednesday, September 10th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.29, for a total value of $145,340.80.
• On Tuesday, September 9th, Jack Bendheim sold 14,080 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.33, for a total value of $567,846.40.

Phibro Animal Health Stock Up 2.0%

NASDAQ PAHC traded up $0.83 during midday trading on Tuesday, hitting $41.45. 362,510 shares of the company traded hands, compared to its average volume of 273,963. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25. The company has a market cap of $1.68 billion, a PE ratio of 35.13, a price-to-earnings-growth ratio of 1.20 and a beta of 0.83. The company's 50-day simple moving average is $37.26 and its 200-day simple moving average is $28.66. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $42.32.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.05. The business had revenue of $378.70 million for the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. As a group, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd were given a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health's dividend payout ratio (DPR) is presently 40.68%.

Analyst Ratings Changes

A number of research firms have recently weighed in on PAHC. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research report on Thursday, August 28th. Bank of America raised their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a research report on Friday, August 29th. JPMorgan Chase & Co. raised Phibro Animal Health from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Weiss Ratings reissued a "hold (c)" rating on shares of Phibro Animal Health in a research report on Tuesday, October 14th. Finally, Zacks Research raised Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $28.40.

Institutional Trading of Phibro Animal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Phibro Animal Health by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company's stock valued at $32,500,000 after buying an additional 6,784 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Phibro Animal Health by 0.5% during the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company's stock valued at $16,713,000 after buying an additional 4,144 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Phibro Animal Health by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company's stock valued at $14,175,000 after buying an additional 7,841 shares during the last quarter. Nuveen LLC purchased a new position in shares of Phibro Animal Health during the 1st quarter valued at about $10,312,000. Finally, Invesco Ltd. raised its stake in shares of Phibro Animal Health by 92.3% during the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company's stock valued at $8,282,000 after buying an additional 186,087 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.